ODI PHARMA AB Total Assets
ODI PHARMA AB total assets. Based on the latest financial reports, ODI PHARMA AB (6OD) holds total assets worth €5.30 Million EUR (≈ $6.20 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of ODI PHARMA AB for the company's overall valuation and market capitalisation.
Total Assets of ODI PHARMA AB (2022–2026)
Total assets of ODI PHARMA AB from 2022 to 2026. This chart illustrates how ODI PHARMA AB's total assets have evolved over time, based on quarterly financial data. See ODI PHARMA AB stock quote for real-time trading data and today's change.
ODI PHARMA AB - Asset Composition Analysis
ODI PHARMA AB Total Assets Breakdown (June 2026)
ODI PHARMA AB total assets breakdown as of June 2026. ODI PHARMA AB's total assets of €5.30 Million consist of 99.8% current assets and 0.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 63.9% |
| Accounts Receivable | €180.64K | 3.4% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2026)
This chart illustrates how ODI PHARMA AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 6OD working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ODI PHARMA AB's current assets represent 99.8% of total assets in 2026, a decrease from 99.9% in 2022.
- Cash Position: Cash and equivalents constituted 63.9% of total assets in 2026, down from 70.2% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 3.4% of total assets.
ODI PHARMA AB Competitors by Total Assets
Key competitors of ODI PHARMA AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
ODI PHARMA AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.81 | 0.86 | 1.09 |
| Quick Ratio | 1.81 | 0.86 | 1.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €2.36 Million | €-579.84K | €521.10K |
ODI PHARMA AB - Advanced Valuation Insights
This section examines the relationship between ODI PHARMA AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.99 |
| Latest Market Cap to Assets Ratio | 0.53 |
| Asset Growth Rate (YoY) | 15.0% |
| Total Assets | €5.30 Million |
| Market Capitalization | $2.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values ODI PHARMA AB's assets below their book value (0.53x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ODI PHARMA AB's assets grew by 15.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ODI PHARMA AB (2022–2026)
The table below shows the annual total assets of ODI PHARMA AB from 2022 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | €5.30 Million ≈ $6.20 Million |
+14.99% |
| 2025-06-30 | €4.61 Million ≈ $5.39 Million |
-62.29% |
| 2024-06-30 | €12.23 Million ≈ $14.29 Million |
+49.37% |
| 2023-06-30 | €8.19 Million ≈ $9.57 Million |
-22.02% |
| 2022-06-30 | €10.50 Million ≈ $12.27 Million |
-- |
About ODI PHARMA AB
ODI Pharma AB (publ), a pharmaceutical company, engages in the production and distribution of pharmaceutical cannabis and cosmetics products in Europe. It offers dried flowers; and cosmetics products. ODI Pharma AB (publ) was founded in 2018 and is based in Stockholm, Sweden.